000126279 001__ 126279
000126279 005__ 20240228140819.0
000126279 0247_ $$2doi$$a10.1007/s00401-015-1410-7
000126279 0247_ $$2pmid$$apmid:25792358
000126279 0247_ $$2pmc$$apmc:PMC4436848
000126279 0247_ $$2ISSN$$a0001-6322
000126279 0247_ $$2ISSN$$a1432-0533
000126279 0247_ $$2altmetric$$aaltmetric:4281053
000126279 037__ $$aDKFZ-2017-02394
000126279 041__ $$aeng
000126279 082__ $$a610
000126279 1001_ $$aCollins, V Peter$$b0
000126279 245__ $$aPilocytic astrocytoma: pathology, molecular mechanisms and markers.
000126279 260__ $$aBerlin$$bSpringer$$c2015
000126279 3367_ $$2DRIVER$$aarticle
000126279 3367_ $$2DataCite$$aOutput Types/Journal article
000126279 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1508405175_6846
000126279 3367_ $$2BibTeX$$aARTICLE
000126279 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126279 3367_ $$00$$2EndNote$$aJournal Article
000126279 520__ $$aPilocytic astrocytomas (PAs) were recognized as a discrete clinical entity over 70 years ago. They are relatively benign (WHO grade I) and have, as a group, a 10-year survival of over 90%. Many require merely surgical removal and only very infrequently do they progress to more malignant gliomas. While most show classical morphology, they may present a spectrum of morphological patterns, and there are difficult cases that show similarities to other gliomas, some of which are malignant and require aggressive treatment. Until recently, almost nothing was known about the molecular mechanisms involved in their development. The use of high-throughput sequencing techniques interrogating the whole genome has shown that single abnormalities of the mitogen-activating protein kinase (MAPK) pathway are exclusively found in almost all cases, indicating that PA represents a one-pathway disease. The most common mechanism is a tandem duplication of a ≈2 Mb-fragment of #7q, giving rise to a fusion between two genes, resulting in a transforming fusion protein, consisting of the N-terminus of KIAA1549 and the kinase domain of BRAF. Additional infrequent fusion partners have been identified, along with other abnormalities of the MAP-K pathway, affecting tyrosine kinase growth factor receptors at the cell surface (e.g., FGFR1) as well as BRAF V600E, KRAS, and NF1 mutations among others. However, while the KIAA1549-BRAF fusion occurs in all areas, the incidence of the various other mutations identified differs in PAs that develop in different regions of the brain. Unfortunately, from a diagnostic standpoint, almost all mutations found have been reported in other brain tumor types, although some retain considerable utility. These molecular abnormalities will be reviewed, and the difficulties in their potential use in supporting a diagnosis of PA, when the histopathological findings are equivocal or in the choice of individualized therapy, will be discussed.
000126279 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000126279 588__ $$aDataset connected to CrossRef, PubMed,
000126279 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b1$$udkfz
000126279 7001_ $$aGiannini, Caterina$$b2
000126279 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-015-1410-7$$gVol. 129, no. 6, p. 775 - 788$$n6$$p775 - 788$$tActa neuropathologica$$v129$$x1432-0533$$y2015
000126279 909CO $$ooai:inrepo02.dkfz.de:126279$$pVDB
000126279 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000126279 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000126279 9141_ $$y2015
000126279 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000126279 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2015
000126279 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126279 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126279 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126279 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000126279 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000126279 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126279 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126279 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126279 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126279 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000126279 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000126279 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bACTA NEUROPATHOL : 2015
000126279 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000126279 980__ $$ajournal
000126279 980__ $$aVDB
000126279 980__ $$aI:(DE-He78)B062-20160331
000126279 980__ $$aUNRESTRICTED